Details for Patent: 9,273,077
Which drugs does patent 9,273,077 protect, and when does it expire?
Patent 9,273,077 protects ALUNBRIG and is included in one NDA.
This patent has fifty-four patent family members in twenty-six countries.
Summary for Patent: 9,273,077
| Title: | Phosphorus derivatives as kinase inhibitors |
| Abstract: | The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use as protein kinase inhibitors. |
| Inventor(s): | Yihan Wang, Wei-Sheng Huang, Shuangying Liu, William C. Shakespeare, R. Mathew Thomas, Jiwei Qi, Feng Li, Xiaotian Zhu, Anna Kohlmann, David C. Dalgarno, Jan Antoinette C. Romero, Dong Zou |
| Assignee: | Takeda Pharmaceutical Co Ltd |
| Application Number: | US13/842,951 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 9,273,077
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-001 | Apr 28, 2017 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) | ⤷ Start Trial | ||||
| Takeda Pharms Usa | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-002 | Apr 28, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) | ⤷ Start Trial | ||||
| Takeda Pharms Usa | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-003 | Oct 2, 2017 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,273,077
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2300013 | ⤷ Start Trial | CA 2019 00028 | Denmark | ⤷ Start Trial |
| European Patent Office | 2300013 | ⤷ Start Trial | 300990 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2300013 | ⤷ Start Trial | PA2019510 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2300013 | ⤷ Start Trial | LUC00120 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 2300013 | ⤷ Start Trial | 122019000046 | Germany | ⤷ Start Trial |
| European Patent Office | 2300013 | ⤷ Start Trial | 2019C/525 | Belgium | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
